Gufic Biosciences Limited receives permission from CDSCO to manufacture Liposomal Amphotericin B Injection

Gufic Biosciences Limited has on May 19, 2021 received permission from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health And Family Welfare, New Delhi to manufacture and market Liposomal Amphotericin B Injection 50mg/vial (Lyophilized), subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

The said injection is used to treat cases of Mucormycosis, also called as Black Fungus that damages the nose, eyes, sinuses, and sometimes even the brain. Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables and it affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immunocompromised individuals, such as cancer patients or people with HIV/AIDS.

The doctors in India are documenting an alarming number of cases of mucormycosis, among patients with COVID-19 and those who have recently recovered as they believe that mucormycosis, may be triggered by the use of steroids, a life-saving treatment for severe and critically ill Covid-19 patients.

The Company is a specialist in the Liposomal technology and has once again stepped ahead to offer Liposomal Amphotericin B, the drug of choice for initial therapy of mucormycosis and a product which is the need of the hour to fight the menace of Black fungus.

Shares of GUFIC BIOSCIENCES LTD. was last trading in BSE at Rs.191.7 as compared to the previous close of Rs. 189.65. The total number of shares traded during the day was 108375 in over 5058 trades.

The stock hit an intraday high of Rs. 197 and intraday low of 188.5. The net turnover during the day was Rs. 20925052.

Source : Equity Bulls

Keywords